Immune response


Last updated: 2022 Jan 25
Total hit(s): 33
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
Both seronegative and seropositive groups were immunogenic to "Sputnik Light" vaccine producing both binding and neutralising antibody responses. It also ellicited cell - mediated immunity along with IFN- secretion. The majority of the solicited adverse events seen in participants vaccinated with "Sputnik Light" were minor and temporary with just 55% of participants having moderate grade adverse effects.
34746910
(Lancet Reg Health Eur)
PMID
34746910
Date of Publishing: 2021 Dec
Title An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine Sputnik Light for prevention of coronavirus infection in healthy adults
Author(s) nameTukhvatulin AI, Dolzhikova IV et al.
Journal Lancet Reg Health Eur
Impact factor
n/a
Citation count: 2
Date of Entry 2022 Jan 25


The vaccine-induced antibody response was high and dose-dependent. Almost all vaccinated volunteers mounted RBD-specific TH1 cell responses which were not dose-dependent. a) This clinical study has several limitations, including a limited sample size and a restriction on people under the age of 55.
b) The induction of tissue-resident memory CD8+ T cells was not evaluated.
c) Reactogenicity was dose-dependent. Adverse events reported were either temporary or spontaneously resolved.
d) Both the immunogenicity rate and CD8+ T cells response strength of the 60 g cohort were lower than the other cohorts, demonstrating the necessity of booster immunisation.
32998157
(Nature)
PMID
32998157
Date of Publishing: 2020 Oct
Title COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Author(s) nameSahin U, Muik A et al.
Journal Nature
Impact factor
24.36
Citation count: 422
Date of Entry 2022 Jan 25


A single dose of an adenoviral vaccine GRAd-CoV2 could be an effective tool for priming a balanced immune response that can then be enhanced to high levels by a single dose of a different vaccine platform. Volunteer F is the lone exception, having received the first BNT162b2 only three days before the week-24 visit, resulting in an excellent internal "no-boost" control.
34737309
()
PMID
34737309
Title Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-CoV2 and BNT162b2 or ChAdOx1-nCOV19
Impact factor
N/A
Date of Entry 2022 Jan 25


In the combined phase 1 and phase 2 trial, the KCONOVOC vaccine elicited a strong immune response. The vaccine induced good antibody response and a moderately good T-cell response. Based on the results, KCONOVOC vaccine at a dose of 5ug in 0/28 regimen was selected for phase 3 clinical trial
33928916
(Chin Med J (Engl))
PMID
33928916
Date of Publishing: 2021 Apr 28
Title Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials
Author(s) namePan HX, Liu JK et al.
Journal Chin Med J (Engl)
Impact factor
1.053
Citation count: 5
Date of Entry 2021 Dec 15


Immunization of mice (C57BL/6 and BALB/c strains) and Pigs with RBD-SpyVLP vaccine showed strong dose-dependent neutralising antibody response. The polyclonal antibody response could recognize key epitopes on RBD (Receptor-Binding Domain). Besides, this vaccine is found to be thermostable making it easier for transportation globally.
33483491
(Nat Commun)
PMID
33483491
Date of Publishing: 2021 Jan 22
Title A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
Author(s) nameTan TK, Rijal P et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 42
Date of Entry 2021 Oct 31


A prefusion-stabilized SARS-CoV-2 spike protein, S-2P was most successful in generating antibodies that neutralised pseudovirus and wild-type live virus when combined with CpG 1018 and aluminium hydroxide adjuvants, with no vaccine-related side effects.
33208827
(Sci Rep)
PMID
33208827
Date of Publishing: 2020 Nov 18
Title Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
Author(s) nameKuo TY, Lin MY et al.
Journal Sci Rep
Impact factor
4.12
Citation count: 33
Date of Entry 2021 Oct 31


Nonhuman primates vaccinated with mRNA-1273 developed a strong immune response. Exposure of vaccinated animals to the SARS-CoV-2 virus protected the animals from infection. There was a significant decrease in the levels of viral RNA in the nasal passage and lungs of vaccinated animals when compared to the control.
32722908
(N Engl J Med)
PMID
32722908
Date of Publishing: 2020 Oct 15
Title Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Author(s) nameCorbett KS, Flynn B et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 368
Date of Entry 2021 Oct 31


In a phase I clinical trial, the DNA vaccine ZyCoV-D was found to be safe and immunogenic. When ZyCoV-D was administered intradermally, it induced good antibody and cellular immune responses. In comparison to the 1 mg vaccination dose, the 2 mg vaccine dose had a greater seroconversion rate, regardless of delivery method. 1) Vaccination with 2mg dose via NFIS was found to elicit significant SARS-CoV-2 specific IgG, neutralising antibody (NAB) titres and decrease in viral load was observed in animals post challenge. 2) No vaccine related severe or solicited adverse events were reported. The adverse events reported were mild to moderate and common.
34308319
(EClinicalMedicine)
PMID
34308319
Date of Publishing: 2021 Aug
Title Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India
Author(s) nameMomin T, Kansagra K et al.
Journal EClinicalMedicine
Impact factor
6.68
Citation count: 13
Date of Entry 2021 Oct 30


In a phase 2 placebo-controlled clinical trial, the mRNA-1273 vaccine induced good immune responses in young adults aged 18 and older. Anti-SARS-CoV-2 spike binding and neutralising antibodies were induced by both doses of the vaccine within 28 days of the first injection and increased to peak titers by 14 days after the second dose. The neutralising antibody levels were higher than levels found in convalescent sera. The mRNA-1273 vaccine was found to be safe and did not induce major adverse events. Longer the interval between the 2 doses, better the induction of antibodies.
33707061
(Vaccine)
PMID
33707061
Date of Publishing: 2021 May 12
Title A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
Author(s) nameChu L, McPhee R et al.
Journal Vaccine
Impact factor
3.31
Citation count: 24
Date of Entry 2021 Oct 30


In the four randomised trials, the ChAdOx1 nCoV-19 (AZD1222) vaccine showed good antibody responses. The antibody responses were more than two-fold higher in participants who received the booster dose after an interval of 12 or more weeks compared with an interval of less than 6 weeks.
33617777
(Lancet)
PMID
33617777
Date of Publishing: 2021 Feb 19
Title Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Author(s) nameVoysey M, Costa Clemens SA et al.
Journal Lancet
Impact factor
43.38
Citation count: 285
Date of Entry 2021 Oct 30


In a placebo-controlled, phase 1/2 clinical trial of two doses of inactivated virus vaccine CoronaVac was found to induce good antibody response in healthy adults aged 1859 years. The vaccine was found to be safe and did not induce any serious adverse events.
33217362
(Lancet Infect Dis)
PMID
33217362
Date of Publishing: 2020 Nov 17
Title Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Author(s) nameZhang Y, Zeng G et al.
Journal Lancet Infect Dis
Impact factor
21.77
Citation count: 334
Date of Entry 2021 Oct 30


Following two doses of AZD1222, spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses were significantly increased in AZD1222-vaccinated persons of all ages.
34189538
()
PMID
34189538
Title T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire
Impact factor
N/A
Date of Entry 2021 Oct 30


The safety, efficacy, and immunogenicity of the BBV152 vaccine were assessed in a multicenter, phase 3 clinical trial. In adults, the BBV152 was immunogenic and efficacious against symptomatic and asymptomatic COVID-19 variant associated disease. The vaccine was well tolerated. with the overall occurance of adverse events being less than that observed in other COVID-19 vaccines
Pre-print ( medRXiv )
Title Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial
Impact factor
N/A
Date of Entry 2021 Oct 30


In a phase IV clinical study, the BNT162b2 mRNA Covid-19 vaccine conferred high neutralising antibody levels (41.18-folds) after the timely administration of the second dose in a population above 85 years of age. Comorbidities in the vaccinated individuals had no significant effect on the antibody response. In the case of chronic comorbidities and cardiovascular diseases, no relation between Type 2 diabetes or High Blood Pressure was associated with vaccine effectiveness. Recipients having a history of heart disease showed low levels of antibody titers after the first dose of the vaccine. No significant difference between genders was observed.
34633648
(Aging Clin Exp Res)
PMID
34633648
Date of Publishing: 2021 Oct 11
Title Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Elderly People Over 85 Years of Age in Greece
Author(s) nameKontopoulou K, Nakas CT et al.
Journal Aging Clin Exp Res
Impact factor
2.37
Citation count: 1
Date of Entry 2021 Sep 27


In phase 1 trial, two doses of SARS-CoV-2 sclamp vaccine, at all doses (5, 15 and 45ug) induced a robust neutralising immune response and a spike glycoprotein-specific T-cell response, which indicates protection against SARS-CoV-2 infection. The presence of the glycoprotein 41 peptide in the clamp caused HIV diagnostic assay interference, posing a potential obstacle to successful implementation and highlighting the need of non-spike directed immunogenicity during vaccine development. Alternative molecular clamp trimerisation domains are being studied to improve this response.
33887208
(Lancet Infect Dis)
PMID
33887208
Date of Publishing: 2021 Apr 19
Title Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial
Author(s) nameChappell KJ, Mordant FL et al.
Journal Lancet Infect Dis
Impact factor
21.77
Citation count: 15
Date of Entry 2021 Sep 27


In two randomised, placebo-controlled, phase1/ 2 trials, RBD dimer-protein subunit vaccine ZF200 was found to be safe and immunogenic. The ZF2001 induced higher neutralising antibody titers than those observed in convalescent individuals. Increasing the vaccine dose from 25 g to 50g did not improve immunogenicity. Three-dose vaccination increased antibody responses when compared to two-dose vaccination. Thus, 25 g antigen with three-dose schedule was selected for evalution of efficacy in phase 3 trials, as it showed higher immunogenicity than 50 g dose in phase 2 trial.
33773111
(Lancet Infect Dis)
PMID
33773111
Date of Publishing: 2021 Mar 24
Title Safety and immunogenicity of a recombinant tandem - repeat dimeric RBD - based protein subunit vaccine (ZF2001) against COVID-19 in adults : two randomised, double - blind, placebo - controlled, phase 1 and 2 trials
Author(s) nameYang S, Li Y et al.
Journal Lancet Infect Dis
Impact factor
21.77
Citation count: 72
Date of Entry 2021 Sep 27


In a placebo-controlled phase 3 clinical trial, rAd26 and rAd5 vector-based heterologous COVID-19 vaccine was found to have good immunogenicity. The vaccine had 91.6% efficacy and a good safety profile.
33545094
(Lancet)
PMID
33545094
Date of Publishing: 2021 Feb 20
Title Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Author(s) nameLogunov DY, Dolzhikova IV et al.
Journal Lancet
Impact factor
43.38
Citation count: 403
Date of Entry 2021 Sep 27


In a randomised, placebo-controlled phase 1 trial, S protein subunit vaccine SCB-2019 without adjuvant had a poor immunogenic response with 3 seroconversions by day 50. However, with adjuvants- either AS03 or CpG/Alum a good humoral and cellular responses were elicited. Based on these results, 9 g SCB-2019 adjuvanted with AS03 and 30 g SCB-2019 adjuvanted with CpG/Alum are the preferred candidates for the phase 2/3 trials. All the formulation had a good safety profile.
33524311
(Lancet)
PMID
33524311
Date of Publishing: 2021 Feb 20
Title Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial
Author(s) nameRichmond P, Hatchuel L et al.
Journal Lancet
Impact factor
43.38
Citation count: 66
Date of Entry 2021 Aug 3


In an open, non-randomised, combined phase 1/2 trial, heterologous vector-based vaccine rAd26 and rAd5 COVID vaccines induced strong humoral and cellular immune responses.
32896291
(Lancet)
PMID
32896291
Date of Publishing: 2020 Sep 26
Title Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Author(s) nameLogunov DY, Dolzhikova IV et al.
Journal Lancet
Impact factor
43.38
Citation count: 327
Date of Entry 2021 Aug 3


In a phase 1/2 trial, ChAdOx1 nCoV-19 vaccine induced both cellular and humoral immune responses. Spike-specific T cells responses were detectable by day 14 and spike-specifc IgG antibodies were detectable by day 28. Both responses were boosted after the second dose. Neutralising antibody responses were seen in all participants after the booster dose.
32702298
(Lancet)
PMID
32702298
Date of Publishing: 2020 Aug 15
Title Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Author(s) nameFolegatti PM, Ewer KJ et al.
Journal Lancet
Impact factor
43.38
Citation count: 825
Date of Entry 2021 Aug 3


In a placebo-controlled, randomised, double-blind phase 2 clinical trial of Adv5 vectored COVID-19 vaccine, it was found that a single dose of 510^10 viral particles was significantly immunogenic. The vaccine-induced seroconversion of neutralising antibodies and good T cell responses.
32702299
(Lancet)
PMID
32702299
Date of Publishing: 2020 Aug 15
Title Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Author(s) nameZhu FC, Guan XH et al.
Journal Lancet
Impact factor
43.38
Citation count: 440
Date of Entry 2021 Aug 3


In phase 1 trial for an inactivated vaccine BBV152, the high neutralising antibody response elicited in phase 1 participants remained elevated even after three months. In the phase 2 trial participants, a better humoral and cell-mediated immune response was produced. The phase 3 trials would be conducted with the 6ug-Algel-IMDG formulation. The study was conducted at a time when the number of COVID-19 cases was increasing in India. The participants in the study could have been exposed to possible infection. In case of such natural exposure to the virus, it is possible the antibody titre values were slightly inflated
33705727
(Lancet Infect Dis)
PMID
33705727
Date of Publishing: 2021 Mar 8
Title Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
Author(s) nameElla R, Reddy S et al.
Journal Lancet Infect Dis
Impact factor
21.77
Citation count: 76
Date of Entry 2021 Jun 22


In phase 1, double blind, randomised trial, the immune response of the BBV152 vaccine was investigated. The vaccine was able to elicit a good immune response.
33485468
(Lancet Infect Dis)
PMID
33485468
Date of Publishing: 2021 Jan 21
Title Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
Author(s) nameElla R, Vadrevu KM et al.
Journal Lancet Infect Dis
Impact factor
21.77
Citation count: 95
Date of Entry 2021 Jun 22


In phase 1, the dose-escalation trial, the immune response of the mRNA-1273 vaccine was assessed. The 100ug dose of the vaccine elicited higher binding- and neutralizing-antibody response than the 25ug dose. Hence, 100ug of the vaccine was used in phase 3.
32991794
(N Engl J Med)
PMID
32991794
Date of Publishing: 2020 Dec 17
Title Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Author(s) nameAnderson EJ, Rouphael NG et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 378
Date of Entry 2021 Jun 22


In a placebo-controlled, observer-blinded, dose-escalation, phase 1 trial, the two vaccine candidates; BNT162b1 and BNT162b2 were observed to have similar immunogenicity. The SARS-CoV-2-neutralizing geometric mean titers, obtained in both the vaccine groups were similar to SARS-CoV-2 convalescent serum samples.
33053279
(N Engl J Med)
PMID
33053279
Date of Publishing: 2020 Dec 17
Title Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Author(s) nameWalsh EE, Frenck RW Jr et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 690
Date of Entry 2021 Jun 22